<DOC>
	<DOCNO>NCT02671500</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability treatment sofosbuvir ( SOF ) /velpatasvir ( VEL ; GS-5816 ) fixed-dose combination ( FDC ) 12 week treatment-naive treatment-experienced participant chronic hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Efficacy Safety Sofosbuvir/Velpatasvir Fixed Dose Combination 12 Weeks Participants With Chronic HCV</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing able provide write informed consent HCV RNA ≥ 10^4 IU/mL screen Chronic HCV infection ( ≥ 6 month ) document prior medical history liver biopsy HCV treatmentnaive ( HCV genotype 1 , 2 , 3 , 4 , 5 , 6 , indeterminate ) treatmentexperienced ( HCV genotype 1 , 2 , 3 , 4 , 5 , 6 , indeterminate ) Liver image within 6 month Day 1 require cirrhotic patient exclude hepatocellular carcinoma ( HCC ) Current prior history clinicallysignificant illness ( HCV ) , gastrointestinal disorder , clinical hepatic decompensation , postoperative condition could interfere absorption study drug Pregnant nursing female male pregnant female partner Chronic liver disease non HCV etiology Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>